{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 18,
  "pageCount": 58,
  "prevPage": 17,
  "nextPage": 19,
  "slideType": "market_landscape",
  "function": "frame_problem",
  "density": "overcrowded",
  "nDataPoints": 10,
  "notes": "The slide highlights the 'me-too' drug development problem in China.",
  "elementsJson": [
    "headline_text",
    "bar_chart_vertical",
    "quote_block"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/18",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-18",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Chasing heated targets without differentiation is unsustainable.",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-f309668dd1b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.92,
        "x": 0.038,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Accumulated number of molecules in the newly started trials of Top 10 targets (2016-21)",
      "attrs": null,
      "subkind": "bar-vertical",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "31aba4b7-59d3-4792-86b1-a174febf04b2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of molecules: 57",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-f8416e661783",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "quote",
      "text": "Chasing heated targets without differentiation is unsustainable. Currently, nearly 100 companies in China have entered PD-1 area, however their efficacy and safety profile are similar, which may lead to a situation like generic drugs...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d223bc4-c62a-479a-b5f8-61758cd08c67",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.92,
        "x": 0.04,
        "y": 0.78
      },
      "kind": "quote",
      "text": "Take monoclonal antibodies as example, 60% of them in China are focused on 5 mechanisms while globally, it is quite diverse with multiple mechanisms. Policy makers have also been aware of the homogeneous competition and are pushing for the adoption of head-to-head comparison with the best SoC...",
      "attrs": null,
      "subkind": "testimonial",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "eeb40f4b-16e9-413d-97a2-eee104188e3b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "quote",
      "text": "Chasing heated targets without differentiation is unsustainable. Currently, nearly 100 companies in China have entered PD-1 area, however their efficacy and safety profile are similar, which may lead to a situation like generic drugs... - Medical Lead, a Chinese biotech, Sept. 2022",
      "attrs": null,
      "subkind": null,
      "toolName": "Authority citation",
      "toolSlug": "authority-citation",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-f5c012997275",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.038,
        "y": 0.91
      },
      "kind": "source-note",
      "text": "Source: DXY, L.E.K. research and analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c4be558d-de78-483f-a6e3-232d9f620092",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.07,
        "w": 0.92,
        "x": 0.038,
        "y": 0.06
      },
      "kind": "title",
      "text": "However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "dadde704-24a0-4a02-aac5-439df3986f05",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.38,
        "x": 0.038,
        "y": 0.03
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "c0afdbbd-3d68-4a4b-8f59-c1f84c7c13f4",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of molecules",
      "numberRaw": "57",
      "numberKind": "plain",
      "actionTitle": "However, past innovation mainly concentrated around heated targets, leading to the rising concern of homogeneous competition for pharmas in China",
      "calloutText": "Chasing heated targets without differentiation is unsustainable.",
      "numberScale": null,
      "numberValue": 57,
      "metricFamily": "volume_count",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}